Headquartered in Georgia but having facilites also in Greenville SC., TGen Tech, LLC is a healthcare company having developed a patented. breakthrough technologies that is targeted at improving soft tissue healing. Current focus on cardiovascular applications. The firm is developing a differentiated Pulmonary Valved Conduit to improve the clinical outcomes of substitute conduit arteries in infants and children with Congenital Heart Defects (CHD). An estimated 2.5 million patients in the US have a CHD, which includes 40,000 newborns annually. Several thousand of these patients have a defect that requires the use of a non-native conduit artery, such as a bovine jugular vein (BJV), to replace structures that are congenitally absent or hypoplastic. TGen Tech uses patented decellularization and physical fixation technology for valved conduit devices to augment the already recognized qualities of BJV and several other cardiovascular applications, including heart valve repair and replacement devices.
